I'm surprised there hasn't been more discussion about this.. Q: How are existing shareholders getting compensated for the transfer or licensing of Sirona Biochem's anti-aging molecule to Sirona Laboratories?
The whole mechanics and lack of transparency on this deal seem very shady to me. The NR word salad is spinning this as a good thing... it is supposed to benefit SBM shareholders 1 - 2 years down the line. But, there is no explanation for how this will happen. No formula for current SBM shareholders to participate or get immediate compensation. This NR is typical SBM - just buying more time and half truths. They claim that this move is not dilutive to existing shareholders... but they removed X% of value from the company... so it is very much dilutive. To me it feels like we just got fleeced.
I could be wrong on all of this... but SBM management at least has a fiduciary duty to explain the details of this deal to ALL the owners/shareholders of SBM.
Some FYI reading about how a spin-off usually works (at least in the US) and how shareholders are compenstated and/or can participate.
https://macabacus.com/restructuring/spin-offs
For me, this is something that should be reported to IROC or BCSC or both.